NASDAQ : SGMT
Sagimet Biosciences Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 10.43 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 739.58M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 703.41M |
| Enterprise Value | 447.79M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 70.34M |
| Shares Outstanding | 70.91M |
| Shares Change (YoY) | +17.03% |
| Shares Change (QoQ) | +63.13% |
| Owned by Insiders (%) | 0.96% |
| Owned by Institutions (%) | 71.19% |
| Float | 64.53M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 392.42 |
| PB Ratio | 2.39 |
| P/TBV Ratio | 2.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 45.02 |
| Quick Ratio | 44.31 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -24.37% |
| Return on Assets (ROA) | -16.41% |
| Return on Invested Capital (ROIC) | -16.94% |
| Return on Capital Employed (ROCE) | -20.40% |
| Weighted Average Cost of Capital (WACC) | 23.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.94M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 3.49 |
| 52-Week Price Change | +19.09% |
| 50-Day Moving Average | 9.93 |
| 200-Day Moving Average | 7.50 |
| Relative Strength Index (RSI) | 53.18 |
| Average Volume (20 Days) | 1,249,257 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 11.53M |
| Short Previous Month | 11.19M |
| Short % of Shares Out | 16.26% |
| Short % of Float | 17.86% |
| Short Ratio (days to cover) | 7.50 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -52.63M |
| Pretax Income | -47.08M |
| Net Income | -47.08M |
| EBITDA | n/a |
| EBIT | -52.63M |
| Earnings Per Share (EPS) | -$1.25 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 240.13M |
| Total Debt | 1.94M |
| Net Cash | 255.62M |
| Net Cash Per Share | $3.60 |
| Equity (Book Value) | 256.16M |
| Book Value Per Share | 4.15 |
| Working Capital | 238.57M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -41.72M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -41.72M |
| FCF Per Share | -$0.59 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -17.03% |
| Shareholder Yield | -17.03% |
| Earnings Yield | -12.59% |
| FCF Yield | -5.93% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $27.91 |
| Price Target Difference | 181.35% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |